title: Design of extended short hairpin RNAs for HIV-1 inhibition.
abstract: RNA interference (RNAi) targeted towards viral mRNAs is widely used to block virus replication in mammalian cells. The specific antiviral RNAi response can be induced via transfection of synthetic small interfering RNAs (siRNAs) or via intracellular expression of short hairpin RNAs (shRNAs). For HIV-1, both approaches resulted in profound inhibition of virus replication. However, the therapeutic use of a single siRNA/shRNA appears limited due to the rapid emergence of RNAi-resistant escape viruses. These variants contain deletions or point mutations within the target sequence that abolish the antiviral effect. To avoid escape from RNAi, the virus should be simultaneously targeted with multiple shRNAs. Alternatively, long hairpin RNAs can be used from which multiple effective siRNAs may be produced. In this study, we constructed extended shRNAs (e-shRNAs) that encode two effective siRNAs against conserved HIV-1 sequences. Activity assays and RNA processing analyses indicate that the positioning of the two siRNAs within the hairpin stem is critical for the generation of two functional siRNAs. E-shRNAs that are efficiently processed into two effective siRNAs showed better inhibition of virus production than the poorly processed e-shRNAs, without inducing the interferon response. These results provide building principles for the design of multi-siRNA hairpin constructs.
authors: Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Meibergdreef 15, Amsterdam, The Netherlands.
authors: Ying Poi
authors: YP
authors: Liu
authors: Joost
authors: J
authors: Haasnoot
authors: Ben
authors: B
authors: Berkhout
mesh_terms: D019380:Anti-HIV Agents / Q000737:chemistry* / Q000494:pharmacology; D002460:Cell Line; D017930:Genes, Reporter; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D016899:Interferon-beta / Q000096:biosynthesis; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000737:chemistry* / Q000494:pharmacology; D022661:RNA, Untranslated / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology
chemical_list: D019380:Anti-HIV Agents; D034741:RNA, Small Interfering; D022661:RNA, Untranslated; D016899:Interferon-beta
references: Gene Ther. 2006 Oct;13(19):1403-13
references: 16708080
references: Nat Genet. 2003 Jul;34(3):263-4
references: 12796781
references: Nat Cell Biol. 2003 Sep;5(9):834-9
references: 12942087
references: Mol Biosyst. 2005 Dec;1(5-6):382-90
references: 16881007
references: Retrovirology. 2006;3:2
references: 16398936
references: J Biomol Tech. 2002 Dec;13(4):265-71
references: 19498992
references: Retrovirology. 2006;3:57
references: 16948865
references: Genes Dev. 2002 Apr 15;16(8):948-58
references: 11959843
references: Nat Biotechnol. 2002 May;20(5):500-5
references: 11981565
references: Nature. 1998 Feb 19;391(6669):806-11
references: 9486653
references: J Virol. 2002 Sep;76(18):9225-31
references: 12186906
references: J Virol. 2006 Aug;80(15):7658-66
references: 16840344
references: Nature. 2000 Mar 16;404(6775):293-6
references: 10749213
references: RNA. 2005 May;11(5):674-82
references: 15811921
references: Nucleic Acids Res. 2005;33(2):796-804
references: 15687388
references: Cell. 2000 Mar 31;101(1):25-33
references: 10778853
references: Mol Cell Biol. 1992 Nov;12(11):5238-48
references: 1357546
references: J Virol. 2003 Nov;77(21):11531-5
references: 14557638
references: Nature. 2001 May 24;411(6836):494-8
references: 11373684
references: Virology. 1991 Dec;185(2):661-72
references: 1683726
references: Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):183-8
references: 12518064
references: Virology. 2006 Feb 20;345(2):457-67
references: 16297951
references: Biochem Soc Trans. 1997 May;25(2):509-13
references: 9191145
references: Nature. 2002 Jul 25;418(6896):435-8
references: 12087358
references: Nat Med. 2002 Jul;8(7):681-6
references: 12042777
references: J Gene Med. 2004 Jul;6(7):715-23
references: 15241778
references: Science. 2002 Apr 19;296(5567):550-3
references: 11910072
references: Nat Biotechnol. 2005 Feb;23(2):227-31
references: 15619616
references: J Virol. 2005 Oct;79(20):12893-904
references: 16188991
references: J Invest Dermatol. 2003 Jun;120(6):990-7
references: 12787126
references: Science. 1999 Oct 29;286(5441):950-2
references: 10542148
references: Gene Ther. 2006 Jun;13(11):883-92
references: 16496015
references: J Virol. 2004 Mar;78(5):2601-5
references: 14963165
references: J Virol. 2000 Apr;74(8):3740-51
references: 10729149
references: Mol Ther. 2007 Mar;15(3):534-41
references: 17213835
references: Mol Ther. 2006 Dec;14(6):883-92
references: 16959541
references: Nature. 2006 May 25;441(7092):537-41
references: 16724069
references: Nucleic Acids Res. 2003 Jul 1;31(13):3406-15
references: 12824337